Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa/carbidopa intraduodenal - AbbVie

Drug Profile

Levodopa/carbidopa intraduodenal - AbbVie

Alternative Names: ABT-SLV187; Carbidopa/levodopa enteral suspension; Carbidopa/levodopa intraduodenal; Duodopa; Duopa; LCIG; Levodopa/carbidopa intestinal gel

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeoPharma
  • Developer AbbVie
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 17 Sep 2019 AbbVie completes the phase III DYSCOVER trial in Parkinson's disease (Late-stage disease) in Finland, Greece, Hungary, Italy, Slovakia, Spain (NCT02799381)
  • 15 Oct 2018 No development reported - Phase-III for Parkinson's disease (Late-stage disease) in Thailand, South Korea, Japan, Taiwan, New Zealand (Intraduodenal)
  • 14 Sep 2018 Launched for Parkinson's disease (Late-stage disease) in Russia (Intraduodenal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top